荃信生物-B(02509)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02509 荃信生物-B

已收盘 01-02 16:08:46

19.580

+0.800

+4.26%

最高19.870	最低18.010	成交量28.76万
今开19.140	昨收18.780	日振幅9.90%
总市值44.25亿	流通市值44.25亿	总股本2.26亿
成交额554.25万	换手率0.13%	流通股本2.26亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02509","market":"HK","secType":"STK","nameCN":"荃信生物-B","latestPrice":19.58,"timestamp":1767341326004,"preClose":18.78,"halted":0,"volume":287600,"delay":0,"floatShares":225999999,"shares":225999999,"eps":-1.7103955725306836,"marketStatus":"已收盘","change":0.8,"latestTime":"01-02 16:08:46","open":19.14,"high":19.87,"low":18.01,"amount":5542518,"amplitude":0.099042,"askPrice":19.8,"askSize":2400,"bidPrice":19.58,"bidSize":200,"shortable":3,"etf":0,"ttmEps":-0.9658883363958698,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1767576600000},"marketStatusCode":5,"adr":0,"listingDate":1710864000000,"exchange":"SEHK","adjPreClose":18.78,"openAndCloseTimeList":[[1767317400000,1767326400000],[1767330000000,1767340800000]],"volumeRatio":0.454318,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02509","defaultTab":"news","newsList":[{"id":"2600450700","title":"智通港股回购统计|1月1日","url":"https://stock-news.laohu8.com/highlight/detail?id=2600450700","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2600450700?lang=zh_cn&edition=full","pubTime":"2026-01-01 09:10","pubTimestamp":1767229801,"startTime":"0","endTime":"0","summary":"其中，回购金额最大的为腾讯控股，回购数量106.10 万，回购金额6.35 亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1387993.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02517","02121","02142","02652","02419","00314","00345","01672","09878","01458","06078","02219","02598","01651","06100","02018","09896","02586","09886","09922","01995","02416","02886","06098","09966","01588","01024","01810","06831","01897","00909","02509","02678","02038","00700","02391","02621","01516","09857","02299","06609","02869","01600","09959","02866","01274","06608","03650","03798","01868"],"gpt_icon":1},{"id":"2595577416","title":"荃信生物-B(02509)12月31日斥资303.05万港元回购16万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2595577416","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595577416?lang=zh_cn&edition=full","pubTime":"2025-12-31 21:38","pubTimestamp":1767188299,"startTime":"0","endTime":"0","summary":"智通财经APP讯，荃信生物-B(02509)发布公告，于2025年12月31日斥资303.05万港元回购16万股。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1387922.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02509"],"gpt_icon":0},{"id":"1183165096","title":"江蘇荃信生物醫藥（02509）回购26.74万股股份，总额约499.71万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1183165096","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1183165096?lang=zh_cn&edition=full","pubTime":"2025-12-30 22:01","pubTimestamp":1767103278,"startTime":"0","endTime":"0","summary":"江蘇荃信生物醫藥股份有限公司于2025年12月30日公告翌日披露报表，披露当日回购股份共267,400股，约占现有已发行股本的0.1183%。每股回购价格介乎每股17.80港元至19.08港元，总金额约499.71万港元。本次回购完成后，公司已发行股本维持225,719,600股，库藏股数量增至1,352,000股，合计已发行股份总数依然为227,071,600股。公司确认已遵守香港联合交易所有限公司《主板上市规则》等相关规定。公告由公司董事会秘書和聯席公司秘書胡衍保签署。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02509"],"gpt_icon":0},{"id":"2595796218","title":"荃信生物JKN2401注射液启动III期临床 适应症为中重度慢性阻塞性肺疾病","url":"https://stock-news.laohu8.com/highlight/detail?id=2595796218","media":"新浪财经","labels":["productRelease","dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595796218?lang=zh_cn&edition=full","pubTime":"2025-12-30 18:30","pubTimestamp":1767090600,"startTime":"0","endTime":"0","summary":"药物临床试验登记与信息公示平台数据显示，江苏荃信生物医药股份有限公司的一项评价皮下注射JKN2401注射液治疗中、重度慢性阻塞性肺疾病有效性、安全性的随机、双盲、安慰剂对照III期临床研究已启动。本次试验主要目的为评价JKN2401注射液治疗中、重度COPD患者的有效性；次要目的包括评价其安全性、药代动力学特征、药效动力学效应及免疫原性。JKN2401注射液为生物制品，适应症为中重度慢性阻塞性肺疾病。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251230183205a489f872&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251230183205a489f872&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02509"],"gpt_icon":0},{"id":"2595279626","title":"每日卖空追踪 | 荃信生物-B 12月30日卖空量成交1.72万股，卖空比例为2.14%","url":"https://stock-news.laohu8.com/highlight/detail?id=2595279626","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595279626?lang=zh_cn&edition=full","pubTime":"2025-12-30 16:30","pubTimestamp":1767083430,"startTime":"0","endTime":"0","summary":"荃信生物-B北京时间12月30日，涨5%，卖空量成交1.72万股，较上一交易日减少12.24%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251230163447a4897f5f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251230163447a4897f5f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02509"],"gpt_icon":0},{"id":"2595641517","title":"荃信生物-B(02509.HK)涨超5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2595641517","media":"每日经济新闻","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595641517?lang=zh_cn&edition=full","pubTime":"2025-12-30 14:57","pubTimestamp":1767077862,"startTime":"0","endTime":"0","summary":"每经AI快讯，荃信生物-B(02509.HK)涨超5%，截至发稿涨5%，报18.9港元，成交额1305.09万港元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202512303605612793.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512303605612793.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["02509","BK1161"],"gpt_icon":0},{"id":"1188151081","title":"江蘇荃信生物（02509）回购9.28万股股份，总额约167.81万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1188151081","media":"公告速递","labels":["shareholding","buyback","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1188151081?lang=zh_cn&edition=full","pubTime":"2025-12-29 22:31","pubTimestamp":1767018672,"startTime":"0","endTime":"0","summary":"江蘇荃信生物醫藥股份有限公司于2025年12月29日发布翌日披露报表，公告回购股份并更新已发行股本变动情况。回购价格区间为每股17.80港元至18.20港元，合计支付约1,678,111.68港元。回购后，公司已发行股份总数仍为227,071,600股，但用于流通的已发行股份数量由226,079,800股减少至225,987,000股，公司库藏股数量相应增至1,084,600股。公司于2025年6月20日获得回购授权，可回购股份总数为22,207,160股。本次公告由董事會秘書和聯席公司秘書胡衍保签署。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,buyback,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02509"],"gpt_icon":0},{"id":"2595735123","title":"荃信生物-B(02509)12月29日斥资167.81万港元回购9.28万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2595735123","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595735123?lang=zh_cn&edition=full","pubTime":"2025-12-29 22:27","pubTimestamp":1767018437,"startTime":"0","endTime":"0","summary":"智通财经APP讯，荃信生物-B(02509)发布公告，于2025年12月29日，该公司斥资167.81万港元回购9.28万股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1386811.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02509","BK1161"],"gpt_icon":0},{"id":"2594226457","title":"创新药BD热后，估值“还债”中","url":"https://stock-news.laohu8.com/highlight/detail?id=2594226457","media":"药闻社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594226457?lang=zh_cn&edition=full","pubTime":"2025-12-27 20:00","pubTimestamp":1766836823,"startTime":"0","endTime":"0","summary":"彼时，市面上甚至还有好几只年内收益翻倍的医药主题基金，BD交易频频刷屏，许多人都相信，“创新药的黄金十年”在二级市场上正在兑现。不少头部及腰部创新药企在年末连续发布了重磅的BD达成公告，交易对象不乏阿斯利康、武田、百时美施贵宝等全球制药巨头，但二级市场的反馈却时常冷淡，股价屡屡出现见光死的行情，市场情绪从期待转为疲软。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251227200212a47ef53b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251227200212a47ef53b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01276","BK1161","01093","BK1574","02509","06978"],"gpt_icon":0},{"id":"2594287939","title":"光鲜下的另一面，BD交易后股价不涨反跌成常态？专家：短期热度降低不是坏事","url":"https://stock-news.laohu8.com/highlight/detail?id=2594287939","media":"时代周报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594287939?lang=zh_cn&edition=full","pubTime":"2025-12-25 14:21","pubTimestamp":1766643688,"startTime":"0","endTime":"0","summary":"今年创新药企业频繁宣布BD交易，但从三季度以来，原本利好的消息却不被二级市场买账。最近一周，BD交易再掀一个小高潮。12月22日，先声药业（02096.HK）宣布其附属公司江苏再明与Ipsen于12月19日签订独家授权许可协议。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512253601825588.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU1064130708.USD","600276","LU0405327148.USD","06978","LU1997245177.USD","LU2097828474.EUR","BK1593","LU1146622755.USD","LU1997245094.SGD","LU2495084118.USD","02142","02509","688336","BK0196","BK1589","LU2097828631.EUR","09995","LU0502904849.HKD","000661","LU1064131003.USD","LU2148510915.USD","BK0057","BK0060","BK0012","LU1781817850.SGD","02096","LU1997244956.HKD","688062","LU2488822045.USD","688331","LU1969619763.USD","LU2097828714.EUR","LU2097828557.USD","01530","BK1574","01167","688428","LU2580892862.HKD","BK0239","BK1161","LU2097828805.USD","LU1328615791.USD","BK0028","BK0183","603087","01801","BK0188","03692","002755","LU0405327494.USD"],"gpt_icon":0},{"id":"2594236714","title":"免疫双抗新药授权出海","url":"https://stock-news.laohu8.com/highlight/detail?id=2594236714","media":"动脉网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594236714?lang=zh_cn&edition=full","pubTime":"2025-12-25 09:51","pubTimestamp":1766627460,"startTime":"0","endTime":"0","summary":"12月19日，荃信生物与Windward Bio附属公司LE2025 Therapeutics AG就QX027N达成授权合作，LE2025获全球开发及商业化QX027N的独家权利，荃信生物将收取最高7亿美元付款，包括首付款、股权、里程碑付款及分级特许权使用费。QX027N是荃信生物自主研发的长效抗TSLPxIL-13双特异性抗体，已获临床试验默示许可，拟用于治疗哮喘及特应性皮炎，现已完成国内I期临床试验首例受试者入组。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251225110822a475bc22&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251225110822a475bc22&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02509"],"gpt_icon":0},{"id":"2594686409","title":"荃信生物-B12月24日遭主力抛售38.9万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2594686409","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594686409?lang=zh_cn&edition=full","pubTime":"2025-12-24 16:15","pubTimestamp":1766564142,"startTime":"0","endTime":"0","summary":"12月24日，荃信生物-B股价收平报18.21元，成交金额527.2万元，换手率0.13%，振幅5.60%，量比1.30。荃信生物-B今日主力资金净流出38.9万元，连续3日净流出，上一交易日主力净流出35.9万元。近一年数据显示，该股主力连续3日净流出后，次日下跌概率为55.56%，平均跌幅为2.52%。该股近5个交易日下跌0.92%，主力资金累计净流出251.4万元，其中1个交易日为股价上涨时净流出；近20日主力资金累计净流入114.5万元，其中净流入天数为6日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251224161935a6c97305&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251224161935a6c97305&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02509"],"gpt_icon":0},{"id":"2593477730","title":"2款国产创新药同日出海，交易总额超17亿美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2593477730","media":"动脉网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593477730?lang=zh_cn&edition=full","pubTime":"2025-12-24 09:41","pubTimestamp":1766540460,"startTime":"0","endTime":"0","summary":"2025年中国药企对外授权活跃，截至10月创新药对外授权总金额达千亿美元，年末继续“多点开花、重点突破”。12月22日，荃信生物与先声药业同日宣布将核心创新药授权国际伙伴，交易总额达17.6亿美元。荃信生物与LE2025 Therapeutics AG签订协议，授权其全球（不含中国内地及港澳台）独家开发及商业化QX027N，将获7亿美元付款，QX027N拟用于治疗哮喘及特应性皮炎，12月已在中国启动I期临床试验；荃信生物近年多次就自研产品达成授权合作。先声药业附属公司江苏再明与Ipsen签订协议，后者获SIM0613大中华区以外全球独家权利，先声药业将收高达10.6亿美元款项。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251224100525a4712269&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251224100525a4712269&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","02509","BK1583","02096","BK1574","BK1161","06978"],"gpt_icon":0},{"id":"2593412728","title":"每日卖空追踪 | 荃信生物-B 12月23日卖空量成交4200股，卖空比例为1.52%","url":"https://stock-news.laohu8.com/highlight/detail?id=2593412728","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593412728?lang=zh_cn&edition=full","pubTime":"2025-12-23 16:30","pubTimestamp":1766478631,"startTime":"0","endTime":"0","summary":"荃信生物-B北京时间12月23日，跌4.46%，卖空量成交4200股，较上一交易日减少89.9%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251223163438a6c51eae&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251223163438a6c51eae&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02509"],"gpt_icon":0},{"id":"2593412723","title":"荃信生物-B盘中异动 临近收盘股价大跌5.56%报18.000港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2593412723","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593412723?lang=zh_cn&edition=full","pubTime":"2025-12-23 15:58","pubTimestamp":1766476715,"startTime":"0","endTime":"0","summary":"2025年12月23日临近收盘15时58分，荃信生物-B股票出现异动，股价急速跳水5.56%。截至发稿，该股报18.000港元/股，成交量25.7万股，换手率0.11%，振幅7.82%。资金方面，该股资金流入260.629万港元，流出217.207万港元。荃信生物-B股票所在的生物技术行业中，整体跌幅为1.84%。其相关个股中，药明巨诺-B、东曜药业-B、昭衍新药涨幅较大，振幅较大的相关个股有翰思艾泰-B、华仁生物-B、药捷安康-B，振幅分别为38.38%、18.07%、17.78%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251223155835a6c4f50c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251223155835a6c4f50c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02509"],"gpt_icon":0},{"id":"2593936724","title":"2025年岁末，国产创新药出海热潮再起！涉及先声药业、荃信生物等","url":"https://stock-news.laohu8.com/highlight/detail?id=2593936724","media":"制药网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593936724?lang=zh_cn&edition=full","pubTime":"2025-12-23 09:42","pubTimestamp":1766454156,"startTime":"0","endTime":"0","summary":"2025年进入12月，国产创新药出海热潮再次掀起。如12月22日，先声药业发布公告，与Ipsen签订了独家授权许可协议，涉及其开发的抗体药物偶联物SIM0613。此外，长春高新、复星医药等多家药企均在本月宣布达成创新药授权合作。从单个企业的零星出海，到产业层面的批量突围，2025年岁末的国产创新药出海热潮，标志着中国医药创新已站在新的历史起点。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251223094420a46c9ab2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251223094420a46c9ab2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1583","BK1191","06978","BK1161","02096","02509","BK1574","02142"],"gpt_icon":0},{"id":"2593177488","title":"港股异动 | 荃信生物-B(02509)涨超4% 双抗新药QX027N授权出海 可获最高7亿美元付款","url":"https://stock-news.laohu8.com/highlight/detail?id=2593177488","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593177488?lang=zh_cn&edition=full","pubTime":"2025-12-22 10:16","pubTimestamp":1766369806,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，荃信生物-B涨超4%，截至发稿，涨4.36%，报19.61港元，成交额309.57万港元。消息面上，荃信生物今早宣布，12月19日，荃信生物与Windward Bio附属公司LE2025 Therapeutics AG就公司自主研发的QX027N达成授权合作。作为回报，荃信生物将有权收取最高7亿美元的付款，包括首付款、Windward Bio的股权、开发及商业里程碑付款，此外，公司还有权根据QX027N在许可地区的销售净额收取分级特许权使用费。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1384236.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"港股异动 | 荃信生物-B(02509)涨超4% 双抗新药QX027N授权出海 可获最高7亿美元付款","news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02509","BK1161"],"gpt_icon":0},{"id":"2593067179","title":"荃信生物-B(02509)与Windward Bio附属公司就QX027N的开发及商业化签订许可及合作协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2593067179","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593067179?lang=zh_cn&edition=full","pubTime":"2025-12-22 08:18","pubTimestamp":1766362723,"startTime":"0","endTime":"0","summary":"智通财经APP讯，荃信生物-B 发布公告，于2025年12月19日，公司与Windward Bio Group AG的附属公司LE2025 Therapeutics AG订立许可及合作协议。该协议授予LE2025在全球范围内开发及商业化QX027N的独家权利。作为回报，公司或其指定附属公司将有权收取总额高达7亿美元的付款，包括首付款、Windward Bio的股权、开发及商业里程碑付款，以及根据QX027N在许可地区的销售净额收取分级特许权使用费。QX027N是公司自主研发的长效抗TSLPxIL-13双特异性抗体。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1384170.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02509"],"gpt_icon":0},{"id":"1167581878","title":"荃信生物-B - 集团将获得最高达7亿美元的付款，包括预付付款等","url":"https://stock-news.laohu8.com/highlight/detail?id=1167581878","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1167581878?lang=zh_cn&edition=full","pubTime":"2025-12-22 08:10","pubTimestamp":1766362209,"startTime":"0","endTime":"0","summary":"荃信生物-B - 集团将获得最高达7亿美元的付款，包括预付付款等","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02509","BK1161"],"gpt_icon":0},{"id":"1173277110","title":"荃信生物-B - Le2025获得全球独家开发QX027n的权利，但不包括中国大陆及其他地区","url":"https://stock-news.laohu8.com/highlight/detail?id=1173277110","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1173277110?lang=zh_cn&edition=full","pubTime":"2025-12-22 08:10","pubTimestamp":1766362208,"startTime":"0","endTime":"0","summary":"荃信生物-B - Le2025获得全球独家开发QX027n的权利，但不包括中国大陆及其他地区。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","02509"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.qyuns.net","stockEarnings":[{"period":"1week","weight":0.0313},{"period":"1month","weight":-0.1354},{"period":"3month","weight":-0.4686},{"period":"6month","weight":0.2258},{"period":"1year","weight":1.5447},{"period":"ytd","weight":1.5447}],"compareEarnings":[{"period":"1week","weight":-0.0073},{"period":"1month","weight":-0.0155},{"period":"3month","weight":-0.0607},{"period":"6month","weight":0.0717},{"period":"1year","weight":0.2777},{"period":"ytd","weight":0.2777}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"江苏荃信生物医药股份有限公司是一家主要从事生物制药的中国公司。该公司主要从事自身免疫及过敏性疾病生物疗法的生物科技研发。该公司业务主要涵盖四大疾病领域，包括皮肤、风湿、呼吸道及消化道疾病。该公司正在研发的项目有8个，目标适应症包括银屑病、特应性皮炎、类风湿性关节炎、炎症性肠病、哮喘等。该公司核心产品有QX002N和QX005N。","exchange":"SEHK","name":"荃信生物-B","nameEN":"QYUNS-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.13","shortVersion":"4.35.13","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"荃信生物-B(02509)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供荃信生物-B(02509)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"荃信生物-B,02509,荃信生物-B股票,荃信生物-B股票老虎,荃信生物-B股票老虎国际,荃信生物-B行情,荃信生物-B股票行情,荃信生物-B股价,荃信生物-B股市,荃信生物-B股票价格,荃信生物-B股票交易,荃信生物-B股票购买,荃信生物-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"荃信生物-B(02509)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供荃信生物-B(02509)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}